Clinical DevelopmentBEAM-302 is expected to differentiate from RNA editing competitors by offering single-course administration, high editing levels, and endogenous control of AAT protein.
Company MilestonesCTA for BEAM-302 Cleared in the U.K., setting up Beam's first in vivo program to enter clinic.
Strategic PartnershipsBEAM-101 has the potential to deliver a superior profile in SCD treatment compared to existing options, with management also being open to partnerships to scale production and expand commercialization.